- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Kabar
-
Kabar
Perawatan Kanker Paru-paru sing Ora Bisa Dioperasi 2026: Terobosan TIL & Bisspesifik Anyar
Konten Pergeseran Paradigma ing Perawatan Kanker Paru-Paru sing Ora Bisa Dioperasi Ngerti Terapi Tumor-Infiltrating Lymphocyte (TIL) Antibodi Bispecific: Pendekatan Dual-Target Analisis Komparatif Eme...
Perawatan Kanker Paru-paru Ambalan 2026: Terobosan Anyar & Pedoman Paling Anyar
Konten Ngerteni Kanker Paru-paru Kambuh ing 2026 Pedoman NCCN Paling Anyar kanggo Terapi Terobosan Kanker Paru-paru Sel Non-Small Recurrent kanggo Strategi Kanker Paru-paru Ambalan kanggo EGFR-Mutant Recu...
Perawatan Kanker Paru-paru Indolent 2026: Protokol Anyar kanggo Urip Jangka Panjang
Konten Ngerti Kanker Paru-paru Indolent ing 2026 Pergeseran Paradigma: Saka Bedah Langsung menyang Pengawasan Aktif Pilihan Bedah Invasif Minimal kanggo Lesi sing Maju Muncul T...
Tahap 2A Perawatan Kanker Paru-paru 2026: Data ELCC Anyar babagan Terapi Neo-Adjuvant
Pangertosan Konten Tahap 2A Kanker Paru-paru Non-Sel Cilik 2026 Terobosan ELCC ing Strategi Neo-Adjuvant Terapi Diangkah kanggo Tahap 2A Kanker Paru-paru sing Mutasi Pembalap Analisis Perbandingan Trea...
Perawatan Kanker Paru Sel Cilik Tahap Ekstensif 2026: Terobosan Iza-bren & Tarlatamab Anyar
Konten Evolusi Perawatan Kanker Paru-paru Sel Cilik Tahap Ekstensif Iza-bren: Pergeseran Paradigma ing Terapi ADC Bispecific Tarlatamab lan Munculé T-Cell Engagers Safety and Tolerability in...
Perawatan Kanker Paru-paru Ambalan 2026: Terobosan Anyar & Pedoman Paling Anyar
Konten Ngerteni Kanker Paru-paru Kambuh ing 2026 Pedoman NCCN Paling Anyar kanggo Terapi Terobosan Kanker Paru-paru Sel Non-Small Recurrent kanggo Strategi Kanker Paru-paru Ambalan kanggo EGFR-Mutant Recu...
